Abstract:Background: DM1 is a multisystem disorder caused by expansion of a CTG triplet repeat in the 3’ non-coding region of DMPK . Neuropsychological consequences and sleep abnormalities are important associations in DM1. Objective: To describe the clinical phenotype, disease progression and characterize the sleep alterations and cognitive abnormalities in a sub-set of patients. Materials and Methods: A retrospective study on 120 genetically confirmed DM1 cases. Findings in neuropsychological assessment and multiple sleep questionnaires were compared with 14 age and sex matched healthy individuals. All 120 patients were contacted through letters/telephonic consultation/hospital visits to record their latest physical and functional disabilities. Results: The mean age at symptom onset was 23.1 ± 11.4 years, M: F = 3.8:1, mean duration of illness = 14.3 ± 9.5 years. Clinically 54.2% had adult onset form, juvenile = 27.5%, infantile = 10.8%, late adult onset = 7.5%. Paternal transmission occurred more frequently. The predominant initial symptoms were myotonia (37.5%), hand weakness (21.7%), lower limb weakness (23.3%) and bulbar (10%). Twenty patients completed sleep questionnaires (SQ). Abnormal scores were noted in Epworth sleepiness scale (55%); Pittsburgh sleep quality index (45%); Berlin SQ (30%); Rapid eye movement sleep Behaviour Disorder SQ (15%); Restless leg syndrome rating scale (10%). Neuropsychological assessment of 20 patients revealed frontal executive dysfunction, attention impairment and visuospatial dysfunction. Frontal lobe was most affected (72%) followed by parietal (16%) and temporal lobe (12%). Conclusions: The current study provides a comprehensive account of the clinical characteristics in Indian patients with DM1. Hypersomnolence was most commonly seen. Excessive daytime sleepiness and Sleep disordered breathing were the most common sleep related abnormality. Cognitive impairment comprised predominantly of frontal lobe dysfunction.

Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1

Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing

Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis.

[Progress of Clinical and Genetic Research on Distal Hereditary Motor Neuropathy].

Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-specific RNA Endonucleases that Target (CUG)n Repeats

Myotonic Dystrophy Type 1 Management and Therapeutics

Myotonic dystrophies: an update on clinical features, molecular mechanisms, management, and gene therapy

microRNA-mRNA expression profiles in the skeletal muscle of myotonic dystrophy type 1

Altered drug metabolism and increased susceptibility to fatty liver disease in myotonic dystrophy

[Clinical and Genetic Analysis of Three Pedigrees Affected with Myotonic Dystrophy].

Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1

Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1

Phase-separated stress granules and processing bodies are compromised in Myotonic Dystrophy Type 1

Cellular Senescence and Aging in Myotonic Dystrophy

Clinical features and genetic spectrum of a multicenter Chinese cohort with myotonic dystrophy type 1

Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1.

Teaching NeuroImages: Myotonic Dystrophy Type 1

Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial

DM1 Transgenic Mice Exhibit Abnormal Neurotransmitter Homeostasis and Synaptic Plasticity in Association with RNA Foci and Mis-Splicing in the Hippocampus

Myotonic Dystrophy Type 1 (DM1): Clinical Characteristics and Disease Progression in a Large Cohort